SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at ...

Objective Asthma and type 2 diabetes are two important causes of morbidity globally. We examined both the association of type ...

Fact checked by Nick Blackmer A new report revealed the U.S. cities with the most seasonal allergies, known as “allergy capitals.”Overall, the southern and eastern parts of the country had the worst ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Researchers discovered lariocidin, a lasso peptide antibiotic that kills multidrug-resistant bacteria by binding a novel ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Session Date and Time: April 30, 2025 - 9:00 AM - 12:00 PM CT (10:00 AM - 1:00 PM ET) Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that the Compensation Committee ...

Past studies have shown that the human sweet taste receptor conveys sweet perception in the mouth and may help regulate glucose metabolism throughout the body.

The B-cell inhibitor approved for use in RA works by attaching to a receptor on the B-cell surface and removing it from circulation. The T-cell inhibitor attaches to a receptor that prevents the T ...

Protein aggregation is the process by which misfolded proteins adopt a conformation that cause its polymerization into aggregates and organized fibrils. Many neurodegenerative diseases ...

After hours: March 26 at 4:02:37 PM EDT Loading Chart for THRD ...